Get the Stockscreener App
10.04
0.00%
0.00
After Hours:
10.04
Translational Development Acquisition Corp stock is traded at $10.04, with a volume of 4,423.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Translational Development Acquisition Corp is a newly organized blank check company.
See More
Previous Close:
$10.04
Open:
$10.0004
24h Volume:
4,423
Relative Volume:
1.03
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.00
$10.04
1-Week Range:
$10.00
$10.04
52-Week Range:
$10.00
$10.05
Translational Development Acquisition Corp Stock (TDACU) Company Profile
Name
Translational Development Acquisition Corp
Sector
Industry
Phone
-
Address
-
Compare TDACU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TDACU
Translational Development Acquisition Corp
|
10.04 | 0 | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
6.92 | 2.00B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
BZAI
Blaize Holdings Inc
|
7.56 | 792.89M | 0 | 0 | 0 | 0.00 |
|
AACT
Ares Acquisition Corporation Ii
|
11.00 | 687.50M | 0 | 16.92M | -1.35M | 0.29 |
|
ANNA
Aleanna Inc
|
11.50 | 466.44M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.51 | 453.24M | 0 | 1.30M | 0 | 0.0301 |
Translational Development Acquisition Corp Stock (TDACU) Latest News
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com Nigeria
TDACU stock touches 52-week low at $10.01 amid market shifts By Investing.com - Investing.com South Africa
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Trident Acquisitions stock hits 52-week high at $10.04 - Investing.com India
Trident Acquisitions stock hits 52-week high at $10.04 By Investing.com - Investing.com UK
Translational Development Acquisition Corp. Announces Closing of $172.5 Million Initial Public Offering, Including Full Exercise of Underwriter's Over-Allotment Option - Finansavisen
Translational Development Acquisition Corp. Announces the Pricing of $150,000,000 Initial Public Offering - The Eastern Progress Online
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - StockTitan
Translational Development Acquisition Corp. (TDACU) Prices $150M IPO - SPACInsider
What’s next for the man charged with killing UnitedHealthcare’s CEO? - 69News WFMZ-TV
Italy's privacy watchdog fines OpenAI for ChatGPT's violations in collecting users personal data - 69News WFMZ-TV
For airports, background music no longer is an afterthought - 69News WFMZ-TV
The Fed expects to cut rates more slowly in 2025. What that could mean for mortgages, debt and more - 69News WFMZ-TV
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
(PDF) Translational Science: A Road Map for the Science of Reading - ResearchGate
Deal Watch: Dealmakers Brace for Impact of Presidential Election - Law.com
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Bruker Completes Asset Acquisition of NanoString Business - Business Wire
Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition - MedCity News
NanoString Technologies to Be Acquired by Bruker Corporation - Business Wire
Initial Public Offering (IPO) News Live Feed - StockTitan
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Organoids Evolve from Academic Marvel to Industrial Tool - Genetic Engineering & Biotechnology News
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases - PR Newswire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
Offerings News Live Feed - StockTitan
NIH launches new initiative: Tackling Acquisition of Language in Kids (TALK) - NIDCD
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD - Business Wire
FirstEnergy issues earnings report - 69News WFMZ-TV
Bollman Hat Company merges with GJ Littlewood & Son - 69News WFMZ-TV
ODDITY Invests $100M to Bring Pharma’s AI Based Molecule Discovery Technology to Beauty and Wellness. - Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
BMS Collaboration Paying Off for Exscientia - Genetic Engineering & Biotechnology News
Developing a metabolic clearance rate framework as a translational analysis approach for hyperpolarized - Nature.com
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
Cultural barriers hinder women’s growth in entrepreneurship - The Malaysian Reserve
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature.com
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Unlocking growth in SMEs: The driving forces of Malaysia’s economy - The Malaysian Reserve
Into Orbit: Satellite Bio Raises $110M toward Tissue Therapeutics - Genetic Engineering & Biotechnology News
Oak Hill Bio Appoints Tauhid Ali CEO - citybiz
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
The Matrix Recellularized: Humacyte Manufactures Bioengineered Human Tissues at Commercial Scale - Genetic Engineering & Biotechnology News
EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies - Business Wire
Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II - Business Wire
Third Rock Ventures Announces Promotion of David Kaufman, M.D., Ph.D., to Partner - Business Wire
Translational Development Acquisition Corp Stock (TDACU) Financials Data
There is no financial data for Translational Development Acquisition Corp (TDACU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.15%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):